Chronic Lymphocytic Leukemia
May 2020 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Authors:Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC
Institution:Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA. The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA. Electronic address: john.byrd@osumc.edu.
Journal:Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.

2:Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
Authors:Risnik D, Colado A, Podaza E, Almejún MB, Elías EE, Bezares RF, Fernández-Grecco H, Seija N, Oppezzo P, Borge M, Gamberale R, Giordano M
Institution:Laboratorio de Inmunologia Oncologica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina. risnikd@upmc.edu.
Journal:Cancer Immunol Immunother. 2020 May;69(5):813-824. doi: 10.1007/s00262-020-02513-y. Epub 2020 Feb 13.

3:Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
Authors:Tambaro FP, Wierda WG
Institution:Dipartimento di Oncoematologia-Unita di trapianto di midollo osseo, UT MD Anderson Cancer Center, Houston, TX, USA; Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy. Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wwierda@mdanderson.org.
Journal:Lancet Haematol. 2020 Feb;7(2):e168-e176. doi: 10.1016/S2352-3026(19)30253-4.

4:A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Authors:Lee CH, Chen PH, Lin C, Wang CY, Ho CL
Institution:Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
Journal:PLoS One. 2020 Jan 29;15(1):e0226879. doi: 10.1371/journal.pone.0226879. eCollection 2020.

5:Machine learning can identify newly diagnosed patients with CLL at high risk of infection.
Authors:Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR, Larsen J, Niemann CU
Institution:Department of Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark. Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Carsten.utoft.niemann@regionh.dk.
Journal:Nat Commun. 2020 Jan 17;11(1):363. doi: 10.1038/s41467-019-14225-8.

6:Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome.
Authors:Pontoizeau C, Girard A, Mesbah H, Haumont LA, Devillers A, Tempescul A, Salaün PY, Lamy T, Le Jeune F, Palard-Novello X
Institution:From the Departments of Nuclear Medicine. Univ Rennes, Department of Nuclear Medicine, CLCC Eugene Marquis, Inserm, LTSI-UMR 1099 Research Unit, Rennes, France.
Journal:Clin Nucl Med. 2020 Feb;45(2):118-122. doi: 10.1097/RLU.0000000000002879.

7:Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
Authors:Molica S, Matutes E, Tam C, Polliack A
Institution:Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy. Department of Hematology, Hadassah-Hebrew-University Medical Center, Jerusalem, Israel.
Journal:Hematol Oncol. 2020 Apr;38(2):129-136. doi: 10.1002/hon.2695. Epub 2019 Dec 10.

8:Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis.
Authors:Javandoost E, Firoozi-Majd E, Rostamian H, Khakpoor-Koosheh M, Mirzaei HR
Institution:Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Journal:Curr Med Chem. 2020;27(2):282-297. doi: 10.2174/0929867326666190911114842.

9:Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Authors:Hanna KS
Institution:Mayo Clinic College of Medicine, Mayo Clinic & University of Minnesota Medical Center, Rochester, MN, USA.
Journal:J Oncol Pharm Pract. 2020 Jan;26(1):146-155. doi: 10.1177/1078155219853030. Epub 2019 Jun 12.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: July 6, 2020
179 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL13744834

Coupon Expires: October 20, 2020



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.